Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.mib.0000231569.43065.a4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System.
Expert Opin Drug Saf
October 2024
Department of Acupuncture and Moxibustion, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China.
Article Synopsis
- Carbamazepine (CBZ) is a widely used medication for epilepsy, but its side effects can complicate treatment, prompting the need for more in-depth studies on adverse drug reactions (ADRs).
- The research utilized the FDA Adverse Event Reporting System (FAERS) database to analyze CBZ-related ADRs, employing various risk detection methods while considering patient demographics like sex and age.
- Findings revealed that common ADRs included hereditary disorders and infections, with notable risks such as bone metabolism issues and ocular problems that are often underreported, highlighting the need for better monitoring and alternative treatment options for high-risk patients.
5% Simvastatin Ointment as Treatment for Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects (CHILD) Syndrome in a 4-year-old Female: A Case Report.
Acta Med Philipp
September 2024
Department of Dermatology, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
A 4-year-old female with Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD) syndrome, with a pathogenic variant of the NSDHL gene, c.130G>A (p.Gly44Ser), and unilateral right-sided erythematous verrucous plaques with scaling and ipsilateral limb defects, was started on 5% simvastatin ointment.
View Article and Find Full Text PDFA rare incidence of severe dermatological toxicities triggered by concomitant administration of all-trans retinoic acid and triazole antifungal in patients with acute promyelocytic leukemia: a case series and review of the literature.
J Med Case Rep
May 2024
Section of Malignant Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan.
Background: All-trans retinoic acid (ATRA) is an indispensable part of the treatment of acute promyelocytic leukemia (APL). Although, mild cutaneous toxicities like mucocutaneous xerosis, rash, and pruritus are well reported, ATRA associated severe dermatological toxicities are extremely rare. ATRA is primary metabolized by cytochrome P450 (CYP450) enzyme system, and triazole antifungals are notorious for their strong inhibitory effect on CYP450.
View Article and Find Full Text PDFEmpowering advanced clinical practitioners in managing acute dermatological emergencies.
Br J Nurs
May 2024
Trainee Advanced Clinical Practitioner, in Acute Medicine, Same Day Emergency Care, Northampton General Hospital NHS Trust.
Advanced clinical practitioners (ACPs) encounter patients with acute dermatological presentations ranging from minor to life-threatening conditions in both primary and secondary care settings. However, ACPs often feel unprepared to assess and treat patients with dermatological emergencies. This article aims to provide guidance to trainee and qualified ACPs, whether in acute hospital settings or primary care, in understanding the essential aspects to consider when consulting with patients presenting with acute dermatological emergencies.
View Article and Find Full Text PDFGlasdegib is a potent, selective, oral inhibitor of the hedgehog signaling pathway. In this phase I study, previously untreated Japanese patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes were treated with glasdegib (100 mg once daily) combinations: low-dose cytarabine (20 mg twice daily; cohort 1, n = 6; expansion cohort, n = 15); daunorubicin and cytarabine (60 mg/m i.v.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!